Cash. And the interns have to count it. PAREXEL announced they will be acquired and taken private by Pamplona Capital later this year. The deal comes after activist investors urged the company to consider a sale due to weak profit margins. Oh, you want specifics? Pamplona will pay $88.10 per share and take on the company’s net debt, bringing the transaction to roughly $5 billion. Josef von Rickenbach, Chairman and CEO of PAREXEL said, “Having considered these opportunities, the [PAREXEL] Board of Directors unanimously determined that this all-cash transaction and the significant, certain value it provides is in the best interest of [PAREXEL] shareholders, as well as our company.” That’s a lot of drugs and a lot of cash (insert misleading image based on sentence).